Scientists at Auburn University have made an important discovery that could improve cancer treatments. Just like a coach ...

BNT327 and ivonescimab are designed to unleash T cells against tumors, like standard checkpoint inhibitors do, while also ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of more tumour types ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

目前国内免疫药物主要有PD-1单抗和PD-L1单抗两大类。大家可能觉得，这两种药物其实是针对同一免疫通路的两个端点，机制上似乎是一致的。其实不然，两者之间存在着一定的区别，无论是在药物设计、作用机制到临床疗效，甚至耐药处理上都有不同之处。今天就全面给 ...